Back to top
more

Kiniksa Pharmaceuticals (KNSA)

(Real Time Quote from BATS)

$18.57 USD

18.57
283,028

+0.69 (3.86%)

Updated Apr 29, 2024 03:55 PM ET

After-Market: $18.54 -0.03 (-0.16%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for KNSA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 206 191 182 324 233
Receivables 21 13 4 0 0
Notes Receivable 0 0 0 0 0
Inventories 31 22 4 0 0
Other Current Assets 18 18 7 10 8
Total Current Assets 276 243 196 333 242
Net Property & Equipment 1 2 3 4 6
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 219 186 0 0 4
Intangibles 17 18 19 0 0
Deposits & Other Assets 1 6 9 6 0
Total Assets 526 460 233 349 255
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8 8 2 1 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 45 30 38 29 20
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 9 6 2 0 0
Total Current Liabilities 64 47 45 32 28
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 12 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 0 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 87 64 48 38 29
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 917 888 860 829 581
Retained Earnings -478 -492 -675 -517 -356
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 439 396 185 312 225
Total Liabilities & Shareholder's Equity 526 460 233 349 255
Total Common Equity 439 396 185 312 225
Shares Outstanding 70.40 69.70 69.90 68.20 54.90
Book Value Per Share 6.23 5.68 2.65 4.57 4.11

Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 214 206 201 185 188
Receivables 16 21 3 25 7
Notes Receivable 0 0 0 0 0
Inventories 27 31 26 24 23
Other Current Assets 14 18 26 12 13
Total Current Assets 271 276 256 246 232
Net Property & Equipment 1 1 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 215 219 194 204 184
Intangibles 17 17 18 18 18
Deposits & Other Assets 4 1 2 2 2
Total Assets 520 526 483 484 443
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 6 8 1 1 1
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 45 45 41 35 21
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 9 9 9 11
Total Current Liabilities 64 64 53 47 37
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 12 12 12 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 2 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 88 87 78 73 53
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 928 917 908 901 894
Retained Earnings -496 -478 -503 -489 -504
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 432 439 405 412 390
Total Liabilities & Shareholder's Equity 520 526 483 484 443
Total Common Equity 432 439 405 412 390
Shares Outstanding 70.60 70.40 70.30 70.10 69.80
Book Value Per Share 6.12 6.23 5.76 5.87 5.59